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Objective: Human papillomavirus (HPV) has been recognized as the major etiologic agent of cervical
squamous cell carcinoma. However, it has been demonstrated that HPV infection is usually a self-limited
process and does not lead to signiﬁcant epithelial lesions or cancer. Recent data indicate that persistent
high-risk HPV (HR-HPV) infections have a signiﬁcantly increased risk of developing incident high-grade
cervical intraepithelial neoplasia and cervical cancer. Our aim, therefore, was to assess whether there
exist HPV genotypes whose persistence can be considered powerful surrogates of a progressive disease.
We retrospectively selected all patients with a negative cytological diagnosis or with atypical squamous
cells of undetermined signiﬁcance, with a positive test for HR-HPV, different from HPV types 16 and 18,
and assessed the signiﬁcance of the risk of progression based on the persistence of the speciﬁc HR-HPV.
Materials and methods: We retrospectively queried the database of our Colposcopy Clinic for all patients
with a negative cytological diagnosis or with atypical squamous cells of undetermined signiﬁcance and a
positive test for HR-HPV, and we calculated the incidence of progression to lesions greater than or equal
to low-grade squamous intraepithelial lesions after 6 months, according to the HPV type.
Results: A progression rate of 48.27% was found in patients tested positive for HPV-31 (Group 1), 38.46%
in patients tested positive for HPV-45 (Group 2), and 5.73% in patients tested positive for HPV types other
than HPV-16, HPV-18, HPV-31, and HPV-45 (Group 3).
Conclusion: Our data demonstrate that the persistence of HPV-31 and HPV-45 is strongly associated with
the occurrence of squamous intraepithelial lesion.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Human papillomavirus (HPV) has been recognized as the major
etiologic agent of most cervical intraepithelial neoplasia (CIN) and
squamous cell carcinoma of the cervix [1,2]. Still today, cervical
cancer is one of the most common female cancers in the world [3].
However, it has been demonstrated that HPV infection is usually a
self-limited process and does not lead to signiﬁcant epithelial le-
sions or cancer. In most cases, the persistence of the viral infection
or the persistence of the contemporary presence of more genotypes
is associated with an increased risk of developing a cervicalhildren and of General and
Naples, Largo Madonna delle
chettino).
bstetrics & Gynecology. Publishedprecursor or an invasive epithelial lesion [4,5]. An infection is
deﬁned to be persistent when it persists for >6e8 months on
average. Introduction of cytological screening has been shown to be
effective in early detection of precursor lesions and has led to a real
reduction of mortality caused by cervical cancer [6,7]. According to
current knowledge, introduction of screening tests also allows to
identify the genotype of the papillomavirus, which is responsible
for cervical infection. The abovementioned tests seem to be of
signiﬁcant help not only in the primary prevention, but also in the
management and follow-up of patients with intraepithelial lesions
of low/high grade (CIN-2e3), and, therefore, is a valuable diagnostic
test in reducing the incidence of carcinoma of the uterine cervix
even more. In particular, the use of HPV testing is essential for the
management of cytological diagnosis of atypical squamous cells of
undetermined signiﬁcance (ASC-US), a broad diagnostic category in
gynecologic cytology that comprises several etiologic processes,by Elsevier Taiwan LLC. All rights reserved.
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tions. Considering the multiplicity of processes included in the
category of ASC-US, execution of HPV testing is crucial in deﬁning
the risk of the existence or appearance of a neoplastic lesion.
Reﬂecting the diversity of pathological changes including ASC-US,
an HPV test is needed to deﬁne the risk of the existence or
appearance of a neoplastic lesion. Recent data indicate that
persistent high-risk HPV (HR-HPV) infections represent a signiﬁ-
cantly increased risk of developing incident high-grade CIN and
cervical cancer [8,9]. Our aim, therefore, was to assess whether
there are genotypes phylogenetically related to HPV-16 or -18, in
particular HPV-31 and -45, which, if persistent, can be considered
powerful surrogates of a progressive disease. Therefore, we retro-
spectively selected all patients who were referred to our clinic with
a negative or ASC-US diagnosis at papanicolaou cytology, with a
positive test for HR-HPV, without evident colposcopic lesions at
ﬁrst diagnosis, and assessed the signiﬁcance of the risk of lesion
progression based on the persistence of speciﬁc genotypes of HR-
HPV, other than HPV-16 or -18.Materials and methods
Patients
This study was approved by the Ethics Committee of our Univer-
sity Department. We retrospectively queried our pathology database
of the Colposcopy Clinic, Department of Women, Children and Gen-
eral and Specialized Surgery, the Second University of Naples, for all
patients with a negative or ASC-US diagnosis at papanicolaou
cytology and a positive HR-HPV test from January 2009 to JanuaryTable 1
Distribution of baseline characteristics among 246 patients with
positive HPV testing.
Demographic variable Patients
Age (y)
30e35 110 (44.71)
35e40 136 (55.29)
Smoking
Never 120 (48.8)
Current 80 (32.5)
Former 46 (18.7)
Age at ﬁrst intercourse
15 55 (22.3)
16e17 73 (29.7)
18e19 68 (27.6)
20 50 (20.3)
No. of sexual partners in lifetime
1 110 (44.7)
2e3 80 (32.5)
4 56 (22.8)
Condom use
Never 98 (39.8)
Rarely 90 (36.6)
Frequently 58 (23.6)
Duration of oral contraceptive use
Never 39 (15.8)
5 y 130 (52.8)
<5 y 77 (31.3)
No. of pregnancies
0e1 108 (43.9)
2e3 82 (33.3)
4 56 (22.8)
History of sexually transmitted diseases
Not reported 179 (72.8)
HPV-associated 21 (8.5)
Other diseases 46 (18.7)
Data are presented as n (%).
HPV ¼ human papillomavirus.2012, and assessed the risk of disease progression. Patients with an
ASC-US diagnosis at papanicolaou cytology and a positive HR-HPV
test were subjected to colposcopy and eventual biopsy. Patients
with an ASC-US diagnosis at papanicolaou cytology and those who
tested negative for HR-HPV tests were not included. In order to avoid
bias related to age [10,11] a homogeneous group of patients, aged
between 30 years and 40 years, was included in our revision. How-
ever, smoking, age of ﬁrst intercourse, the number of sexual partners
in their lifetime, condom use, duration of oral contraceptive use,
numbers of pregnancies, and a history of sexually transmitted dis-
eases are to be considered as confounding factors within HPV infec-
tion. Distribution of baseline characteristics is illustrated in Table 1.
The variability of the sample did not allow us to evaluate the asso-
ciationof each factorwith the statusofHPV. This remains an objective
of future study. Women were eligible for inclusion if they were not
pregnant, had an intact uterus, reported no referral for hysterectomy,
did not use vaginal estrogen medication in the previous 6 months,
and did not undergo treatment for cervical disease by electro-
coagulation, cryotherapy, or conization in the previous 6 months.
All patients with a positive test for HPV-16 and -18 were
excluded for the established role of these two genotypes on the
development of intraepithelial neoplasia and cancer of the cervix.
Our aim was to assess whether there are other genotypes that can
signiﬁcantly predict the progression to neoplastic lesions. We
considered a positive cytological progression when the follow-up
cytological diagnosis was one of the following: Atypical Squa-
mous Cells (ASC-H), cannot exclude a high-grade squamous intra-
epithelial lesion, low-grade squamous intraepithelial lesion (L-SIL,
which cannot exclude high-grade SIL) or squamous cell carcinoma
or adenocarcinoma. Positive histological progression was deﬁned
as colposcopic biopsy showing mild (CIN-1), moderate (CIN-2), or
severe squamous dysplasia (CIN-3) 60 days after the negative or
ASC-US cytological diagnosis. In all the patients included, a
concordance between the cytological and histological progression
was found. Therefore, the squamous intraepithelial lesion was al-
ways conﬁrmed by cytological and histological examination. The
time of progression was calculated as the number of months
intervening between the ﬁrst diagnosis and the follow-up. The ﬁrst
follow-up after the diagnosis was not made before 180 days.
Cytological and surgical pathology follow-up reports were
reviewed for all specimens available, including pap smears, bi-
opsies and resections, and follow-up documentation.
HPV molecular testing
The presence of HPVwas assessed by the linear array test (Roche
Molecular Diagnostics, Milan, Italy). This test is a qualitative in vitro
test for the detection of HPV in clinical specimens. The test utilizes
ampliﬁcation of target DNA by polymerase chain reaction and
nucleic acid hybridization, and detects 37 anogenital HPV DNA
genotypes [6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54,
55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73 (MM9), 81, 82
(MM4), 83 (MM7), 84 (MM8), IS39, and CP6108] in cervical cells
collected in PreservCyt solution [12].
Cytological diagnosis
Cytological diagnosis was made by conventional pap smear,
without any knowledge of the HPV test results. Cytopathology re-
ports were based on the Bathesda system for cytological diagnoses.
For the purpose of this analysis, the following categories were used:
within normal limits or benign cellular changes (normal); ASC-US
or atypical glandular cells of undetermined signiﬁcance; L-SIL;
high-grade SIL; and cancer. Criteria for ASC-US and positive
cytology were used in accordance with the 2001 Bethesda system
Fig. 2. Risk of progression, intended as the risk of decreased survival. p < 0.001 (log-
rank test). n events mean se(mean) median 0.95LCL 0.95UCL.
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criteria included nuclei 2.5e3 larger than an intermediate squa-
mous cell nucleus, increased nuclearecytoplasmic ratio, minimal
hyperchromasia and chromatin irregularities, and rarely “atypical
parakeratosis.” All detected events of high-grade SIL were referred
for colposcopic follow-up and biopsy if required, according to the
National Institute of Health-approved guidelines.
Statistical analyses
Time to progression was determined as the number of months
from baseline (initial positive HPV molecular test) to ﬁrst pro-
gression, and it was described using ranges, interquartile ranges,
and medians, and illustrated using KaplaneMeier curves. Risk of
progression, intended as the risk of decreased survival over time
(months), was compared between HPV groups using log-rank test.
A p value of <0.05 was considered statistically signiﬁcant.
Results
Analyzing our database, we selected 246 patients with an average
age of 34 (±3.2) years, fulﬁlling the inclusion criteria of the study,with
a negative or an ASC-US cytological diagnosis, positive HR-HPV ge-
notypes other than HPV-16 or -18, and negative colposcopy. We
divided the patients according to the HPV types found and the inci-
dence of onset of any neoplastic lesions diagnosed at the ﬁrst follow-
up, which occurred 180 days after the ﬁrst negative or ASC-US diag-
nosis. Based on the viral type frequency, we divided the patients into
three groups: Group 1dpatients tested positive for HPV-31; Group
2dpatients tested positive for HPV-45; and Group 3dpatients tested
positive for HPVs different from HPV-16, -18, -31, and -45.
At 6 months, according to the HPV types and the incidence of
progression to lesions greater than or equal to L-SIL, a progression
rate of 48.27% (±1.3%) was observed in patients tested positive for
HPV-31 (Group 1), 38.46% (±1.8%) in those tested positive for HPV
45 (Group 2), and 5.73% (±2.1%) in those tested positive for HPVs
different from HPV-16, -18, -31, and -45 (Group 3).
The results are summarized in Fig. 1. When stratifying the risk of
progression, intended as the risk of decreased survival, by HPV
genotypes, KaplaneMeier curves demonstrated statistically sig-
niﬁcant differences (log-rank test p < 0.001). statistical analysis is
illustrated in Fig. 2.
Discussion
Cervical cancer remains a major health problem and is the ﬁrst
cancer to be recognized by the World Health Organisation asFig. 1. Results after 6 months. HPV ¼ human papillomavirus; HR-HPV ¼ high-risk
human papillomavirus.entirely attributable to infections [13e15]. The high-risk viral types
most frequently implicated in cervical carcinoma are type 16 that
are responsible for 60% of all the cases of this neoplastic disease,
followed by type 18, responsible for about 10% of cases. Therefore,
approximately 70% of all cervical carcinomas are associated with
the presence of HPV-16 or -18 [16e19]. The natural history of
infection is strongly inﬂuenced by the balance established between
host and infecting agents. Indeed, there are three possibilities of
developing an HPV infection: regression, persistence, and pro-
gression. Around 70e90% of papillomavirus infections are transi-
tory because the virus is eliminated by the immune system before it
develops a pathogenic effect. The persistence of the viral infection,
on the other hand, is a prerequisite for the evolution of cancer. The
acquisition of a viral genotype at high risk increases the probability
of persistent infections. In this case, one can develop precancerous
lesions, which may then progress to cervical cancer. In addition,
from the data obtained in our study, a different probability of
incidence of onset and evolution of lesions related to HPV,
depending on the genotypes of persistent HR-HPV [20,21], has been
found. In particular, an increased incidence of onset of lesions
greater than or equal to L-SIL was noticed in the case of persistence
of HPV-31 and -45 infections, or rather genotypes phylogenetically
related to HPV-16 or -18. Our data are certainly preliminary; further
investigations and a larger sample size are required to validate the
ﬁndings. However, if conﬁrmed, the implications would be
certainly signiﬁcant, since 30% of cases of cervical cancer, which are
not HPV-16 or -18 related, may be involved. Furthermore, our data
can be extremely useful for the purposes of primary prophylaxis by
vaccination, in case of patients who are already positive for HPV-16
or -18. It has been demonstrated that the vaccine formulations
available in the market, in particular the bivalent form, indeed offer
a cross-protection for the HPV genotypes -31 and -45 that are
phylogenetically similar to -16 and -18, respectively. Such evidence,
in accordance with the data of the present study, suggests that
these genotypes indeed have similar gene sequences. In particular,
it is assumed that this type of gene concordance is found in speciﬁc
transcription factors: capsid proteins and E6eE7 proteins
(responsible for the immortality of cells). From our ﬁndings, it has
been proved that cytology triage with HR-HPV testing is more
sensitive and speciﬁc than conventional cytology triage [6,22]. HPV
testing is an important ancillary diagnostic tool in identifying
women who are at risk of progression to SIL, when the number of
colposcopy referrals and follow-up tests [6,22] decreases. For this
reason, it is necessary to have validated molecular tests for the
identiﬁcation of viral antigens in biological samples, in order to
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the triage of womenwith ambiguous or borderline cervical smears
[23,24].
In conclusion, our data demonstrate that not only the persis-
tence of HR-HPV is strongly associated with the occurrence of SIL,
but also this association increases in case of particular genotypes
phylogenetically similar to genotypes 16 and 18, such as types 31
and 45.
The overwhelming positive associations, identiﬁed in our study
and conﬁrmed by the current available data, validate the use of HPV
persistence as a surrogate endpoint in clinical trials and potentially
in cervical cancer screening. With standardization of deﬁnitions
and testing, detection of persistent HPV DNA can become a valuable
marker of CIN-2e3 and cancer for clinical and research
applications.
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